# Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine

> **NCT00365144** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 36 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** erlotinib hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00365144
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2009-01
- **Final completion:** 2010-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365144, "Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine". Retrieved via MORVS 2026-10-26 from https://api.morvs.ai/clinical/NCT00365144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*